Form 8-K - Current report:
SEC Accession No. 0001104659-24-077762
Filing Date
2024-07-03
Accepted
2024-07-03 16:02:06
Documents
14
Period of Report
2024-06-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2418883d1_8k.htm   iXBRL 8-K 28291
2 EXHIBIT 10.1 tm2418883d1_ex10-1.htm EX-10.1 63892
  Complete submission text file 0001104659-24-077762.txt   282995

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA alms-20240627.xsd EX-101.SCH 3009
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE alms-20240627_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alms-20240627_pre.xml EX-101.PRE 22355
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2418883d1_8k_htm.xml XML 3679
Mailing Address 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 650-231-6625
ALUMIS INC. (Filer) CIK: 0001847367 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42143 | Film No.: 241100003
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)